TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
DFTX

Definium Therapeutics, Inc.

Healthcare · Biotechnology · —

36.70$ -2.4% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

All figures as a percentage of total assets in the same period.

Tick rows to compare them in a chart (up to 4)

Balance Sheet DFTX
Line item 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
63.9% 67.2% 44.0% 5.6% 100.0% 100.0% 83.7% 85.9% 83.4% 93.2% 95.3%
1.6% 5.4% 0.1% 4.4% 0.6% 98.3% 81.4% 83.6% 80.1% 90.6% 58.6%
63.1% 63.8% 42.0% 4.4% 0.6% 98.3% 81.4% 83.6% 80.1% 90.6% 93.5%
0.1% 2.4% 0.3% 0.2% 0.2% – – – – – –
0.0% 0.0% – 0.0% 0.0% – – – – – –
– – – – – – 12.1% 11.7% 16.0% 6.6% 4.5%
– – – – – – 4.2% 2.2% 0.4% – –
2.6% 37.2% 2.0% 0.2% 6.8% 6.9% 7.5% 11.2% 37.3% 20.1% 24.5%
2.6% 37.2% 2.0% 0.2% 6.8% 3.7% 6.3% 10.5% 25.9% 12.9% 15.2%
– – 0.4% – – – – 0.0% – – –
– – – – – 2.5% 2.5% 1.2% 3.3% 0.7% 1.2%
– – – – – – – – 11.3% 7.2% 9.2%
97.4% 62.8% 98.0% 99.8% 93.2% 93.1% 92.5% 88.8% 62.7% 79.9% 75.5%
-107.5% -246.5% -45.1% -73.2% -124.3% -54.8% -83.9% -114.4% -233.0% -132.0% -132.4%
27.1% 39.7% 6.3% 8.8% 12.9% 21.8% 16.7% 18.2% 31.4% 233.2% 20.3%

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?